PNC Financial Services Group’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.55M Buy
40,301
+828
+2% +$85.9K ﹤0.01% 891
2026
Q2
$3.85M Buy
39,473
+2,113
+6% +$185K ﹤0.01% 827
2026
Q1
$3.14M Buy
37,360
+139
+0.4% +$8.05K ﹤0.01% 852
2025
Q4
$1.53M Hold
37,221
– – ﹤0.01% 1077
2025
Q3
$1.46M Buy
37,221
+121
+0.3% +$3.09K ﹤0.01% 1080
2025
Q2
$691K Hold
37,100
– – ﹤0.01% 1349
2025
Q1
$673K Hold
37,100
– – ﹤0.01% 1344
2024
Q4
$809K Hold
37,100
– – ﹤0.01% 1259
2024
Q3
$1.02M Hold
37,100
– – ﹤0.01% 1162
2024
Q2
$960K Hold
37,100
– – ﹤0.01% 1154
2024
Q1
$1.11M Buy
+37,100
New +$806K ﹤0.01% 1114

Other funds holding DNTH

PNC Financial Services Group's DNTH Position: Q3 2026 in Review

PNC Financial Services Group increased its Dianthus Therapeutics (DNTH) stake by 2.1% in Q3 2026, buying an estimated $85.9K and bringing the position to 40,301 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #891.

PNC Financial Services Group first reported a position in DNTH in Q1 2024 and has held it in 11 quarters since. The position peaked at $3.85M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • PNC Financial Services Group held 40,301 shares of Dianthus Therapeutics worth $3.55M as of Q3 2026.
  • PNC Financial Services Group bought 828 Dianthus Therapeutics shares in Q3 2026, an estimated $85.9K.
  • Dianthus Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #891 holding.
  • PNC Financial Services Group first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • PNC Financial Services Group's Dianthus Therapeutics position peaked at $3.85M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.